MétaCan
Menu
Back to cohort
Record W2270912873

Low BRCA1 and ERCC1 mRNA expression correlates with improved survival in ovarian cancer patients

2007· article· en· W2270912873 on OpenAlexaboutno aff
Johanne I. Weberpals, Katherine V. Clark-Knowles, L. Haidari, Olga Antoniouk, Jim Dimitroulakos

Bibliographic record

VenueMolecular Cancer Therapeutics · 2007
Typearticle
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsnot available
Fundersnot available
KeywordsERCC1Ovarian cancerOncologyChemotherapyInternal medicineStage (stratigraphy)MedicineBiologyCisplatinCancerSurvival analysisCancer researchNucleotide excision repairDNA repairGene
DOInot available

Abstract

fetched live from OpenAlex

A199 The poor prognosis of advanced-stage ovarian cancer is marked by early recurrences and resistance to platinum-based chemotherapy. Elevated levels of the DNA repair proteins, Breast Cancer 1 (BRCA1) and excision repair cross complementation group 1 (ERCC1) have been associated with increased resistance to cisplatinum in various malignancies including ovarian cancer. Purpose: The aim of this study was to analyze BRCA1 and ERCC1 mRNA expression as markers of recurrence and prognosis in ovarian cancer. Experimental procedures: Clinicopathologic data was collected on 22 patients who underwent surgical staging and adjuvant chemotherapy at The Ottawa Hospital between 2000 and 2005. RNA was extracted from frozen tissue in the Ottawa Ovarian Tissue Bank and mRNA expression was determined by quantitative, real-time, reverse-transcriptase PCR (Q-PCR). Kaplan-Meier survival curves and regression analyses were determined using Prism software. The A2780s ovarian cell line, which has high expression of both BRCA1 and ERCC1, was exposed to a number of drugs including chemotherapy and molecular inhibitors and analyzed by the MTT cell viability assay. Results: Linear regression analysis demonstrated that both low BRCA1 and ERCC1 expression were associated with improved survival ( P=0.048 and P=0.033) but only low BRCA1 correlated with a longer TTP (P=0.047 and P=0.122, respectively). Patients were classified into relative high and low mRNA expression levels for BRCA1. There was no significant difference between the two groups with respect to the distribution of independent variables, age, stage, residual disease status, grade and p53 IHC score. The median OS by Kaplan-Meier estimates for BRCA1-low was 51 months, and for BRCA1-high was 37 months, illustrating a trend that patients with decreased BRCA1 expression have a more favorable survival (P=0.079). The median TTP was 20.5 months in BRCA1-low and 12.5 months in BRCA1-high, but the distribution between groups was not significantly different in this patient cohort (P=0.384). Exposure of the A2780s cell line to a number of therapeutic agents either alone or in combination, resulted in differential drug sensitivity. Conclusions: Low BRCA1 and ERCC1 expression correlates with improved survival and may be useful to tailor chemotherapeutic approaches in the treatment of ovarian cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.273
Teacher spread0.260 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2007
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicOvarian cancer diagnosis and treatmentFrench-language works237,207